131I-chTNT (Tumor Necrosis Therapy-1; 131I-TNT, Cotara®, Vivatuxin®, 131I-derlotuximab biotin – new adopted USAN name February 2015) is a DNA/histone-targeting monoclonal antibody developed originally to treat brain cancer through in situ infusion directly into the tumor under the name Cotara. The drug has been granted orphan drug status and fast-track designation for the treatment of glioblastoma multiform (GBM) and anaplastic astrocytoma by the FDA. The drug reached Phase III clinical trial. Unfortunately, one can consider that development of this drug in GBM patients is discontinued.
In parallel, the product was introduced on the Chinese market for the treatment of lung cancer in January 2007 under the brand name Vivatuxin®.
In China, this drug is further under clinical development for brain and liver cancer.
Leading Emitter: beta electrons (β–)